Expanding diagnostics MicroGenDX offers qPCR plus NGS infectious disease testing, with AMA/Medicare billing support and CAP/CLIA certification, indicating a scalable, billable platform attractive to large hospital systems and healthcare networks seeking advanced diagnostic capabilities.

Broad market reach Trusted by over 39,000 physicians and serving more than 900,000 patients, MicroGenDX demonstrates broad clinical adoption across hospitals, long-term care, dental, and veterinary settings, presenting opportunities to upsell to multi-site healthcare groups and integrated care providers.

Rapid, actionable data NGS-based detection provides faster, more comprehensive pathogen identification at species or strain level, enabling accelerated treatment decisions and potential collaboration with antimicrobial stewardship programs in hospitals and long-term care facilities.

Strategic partnerships Past collaborations with Evvy and regional labs indicate appetite for partnerships to extend reach and capabilities; pursue alliances with wellness, gender health, and telemedicine players, as well as regional labs seeking FDA-authorized, cost-effective diagnostics.

Growth channels Recent product launches such as Rapid H5 and patient-focused website point to customer-centric initiatives and digital access improvements; leverage digital marketing, direct-to-physician channels, and site expansion in new geographies to drive adoption and cross-sell complementary testing panels.